FDA Inspection
Charu Aggarwal, MD, MPH, Hematology-Oncology DivisionCharu Aggarwal, MD, MPH, Hematology-Oncology Division – FDA Inspection, Mar 28, 2017
Record Details
This FDA Inspection record concerns Charu Aggarwal, MD, MPH, Hematology-Oncology Division, with an inspection on March 28, 2017, issued by the Center for Drug Evaluation and Research, covering drugs.
- Inspection Date
- March 28, 2017
- Product Type
- Drugs
- Person
- Marcelo O. Mangalindan (Issuing Officer)
View Company Profile
ID · 47299dc4-c9e5-426e-b63d-33cf9ceec5b8
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1017164
- FDA center
- Human Drugs
- Project area
- Bioresearch Monitoring
- Outcome
- Form 483 issued
FDA Citations
2- 21 CFR 312.60FD-1572, protocol compliance
- 21 CFR 312.62(b)Case history records- inadequate or inadequate
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Charu Aggarwal, MD, MPH, Hematology-Oncology Division
1| Date | Classification | Office | Project area |
|---|---|---|---|
| July 20, 2026 | Not classified | Philadelphia District Office |
Other documents for Charu Aggarwal, MD, MPH, Hematology-Oncology Division
- FDA Inspection 1331848 - 2026-07-20
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.